Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.21
DVA's Cash to Debt is ranked lower than
57% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 0.29 vs. DVA: 0.21 )
Ranked among companies with meaningful Cash to Debt only.
DVA' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 0.11 Max: 5.2
Current: 0.21
0
5.2
Equity to Asset 0.26
DVA's Equity to Asset is ranked lower than
74% of the 219 Companies
in the Global Medical Care industry.

( Industry Median: 0.45 vs. DVA: 0.26 )
Ranked among companies with meaningful Equity to Asset only.
DVA' s Equity to Asset Range Over the Past 10 Years
Min: 0.03  Med: 0.25 Max: 0.7
Current: 0.26
0.03
0.7
Interest Coverage 4.61
DVA's Interest Coverage is ranked lower than
67% of the 157 Companies
in the Global Medical Care industry.

( Industry Median: 9.36 vs. DVA: 4.61 )
Ranked among companies with meaningful Interest Coverage only.
DVA' s Interest Coverage Range Over the Past 10 Years
Min: 3.33  Med: 4.42 Max: 5.47
Current: 4.61
3.33
5.47
F-Score: 6
Z-Score: 2.02
M-Score: -2.47
WACC vs ROIC
5.61%
7.53%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 10.15
DVA's Operating margin (%) is ranked higher than
62% of the 219 Companies
in the Global Medical Care industry.

( Industry Median: 7.46 vs. DVA: 10.15 )
Ranked among companies with meaningful Operating margin (%) only.
DVA' s Operating margin (%) Range Over the Past 10 Years
Min: 13.18  Med: 15.52 Max: 17.15
Current: 10.15
13.18
17.15
Net-margin (%) 3.56
DVA's Net-margin (%) is ranked lower than
54% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 4.28 vs. DVA: 3.56 )
Ranked among companies with meaningful Net-margin (%) only.
DVA' s Net-margin (%) Range Over the Past 10 Years
Min: 5.38  Med: 6.58 Max: 7.69
Current: 3.56
5.38
7.69
ROE (%) 9.58
DVA's ROE (%) is ranked higher than
52% of the 204 Companies
in the Global Medical Care industry.

( Industry Median: 9.24 vs. DVA: 9.58 )
Ranked among companies with meaningful ROE (%) only.
DVA' s ROE (%) Range Over the Past 10 Years
Min: 15.06  Med: 21.52 Max: 33.29
Current: 9.58
15.06
33.29
ROA (%) 2.62
DVA's ROA (%) is ranked lower than
59% of the 222 Companies
in the Global Medical Care industry.

( Industry Median: 3.42 vs. DVA: 2.62 )
Ranked among companies with meaningful ROA (%) only.
DVA' s ROA (%) Range Over the Past 10 Years
Min: 3.83  Med: 5.19 Max: 5.69
Current: 2.62
3.83
5.69
ROC (Joel Greenblatt) (%) 47.22
DVA's ROC (Joel Greenblatt) (%) is ranked higher than
76% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 19.71 vs. DVA: 47.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DVA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 46.66  Med: 57.10 Max: 68.47
Current: 47.22
46.66
68.47
Revenue Growth (3Y)(%) 19.10
DVA's Revenue Growth (3Y)(%) is ranked higher than
86% of the 160 Companies
in the Global Medical Care industry.

( Industry Median: 8.20 vs. DVA: 19.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DVA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -87.6  Med: 15.80 Max: 39.8
Current: 19.1
-87.6
39.8
EBITDA Growth (3Y)(%) 13.00
DVA's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 128 Companies
in the Global Medical Care industry.

( Industry Median: 7.90 vs. DVA: 13.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DVA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -88.4  Med: 16.50 Max: 98.7
Current: 13
-88.4
98.7
EPS Growth (3Y)(%) 9.00
DVA's EPS Growth (3Y)(%) is ranked higher than
50% of the 121 Companies
in the Global Medical Care industry.

( Industry Median: 9.00 vs. DVA: 9.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DVA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -29  Med: 15.90 Max: 125.5
Current: 9
-29
125.5
» DVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

DVA Guru Trades in Q1 2015

Manning & Napier Advisors, Inc 1,380,360 sh (New)
Arnold Van Den Berg 163,503 sh (New)
Andreas Halvorsen 6,362,827 sh (+42.45%)
Steve Mandel 5,455,774 sh (+38.47%)
Ray Dalio 55,326 sh (+10.59%)
Alan Fournier 2,245,997 sh (unchged)
Warren Buffett 38,565,570 sh (unchged)
Joel Greenblatt Sold Out
Mario Gabelli 39,663 sh (-7.25%)
Steven Cohen 80,400 sh (-57.84%)
Pioneer Investments 311,542 sh (-61.17%)
Jim Simons 157,600 sh (-61.95%)
Paul Tudor Jones 3,500 sh (-72.90%)
» More
Q2 2015

DVA Guru Trades in Q2 2015

Jim Simons 726,600 sh (+361.04%)
Steven Cohen 118,600 sh (+47.51%)
Ray Dalio 79,526 sh (+43.74%)
Paul Tudor Jones 4,700 sh (+34.29%)
Mario Gabelli 41,763 sh (+5.29%)
Manning & Napier Advisors, Inc 1,421,635 sh (+2.99%)
Steve Mandel 5,455,774 sh (unchged)
Warren Buffett 38,565,570 sh (unchged)
Pioneer Investments Sold Out
Alan Fournier 2,158,397 sh (-3.90%)
Arnold Van Den Berg 153,928 sh (-5.86%)
Andreas Halvorsen 4,968,551 sh (-21.91%)
» More
Q3 2015

DVA Guru Trades in Q3 2015

Joel Greenblatt 48,381 sh (New)
Arnold Van Den Berg 285,918 sh (+85.75%)
Steve Mandel 7,918,998 sh (+45.15%)
Warren Buffett 38,565,570 sh (unchged)
Mario Gabelli 41,763 sh (unchged)
Louis Moore Bacon 50,000 sh (unchged)
Ray Dalio Sold Out
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Manning & Napier Advisors, Inc 1,405,605 sh (-1.13%)
Alan Fournier 1,999,797 sh (-7.35%)
Jim Simons 408,600 sh (-43.77%)
Andreas Halvorsen 2,735,075 sh (-44.95%)
» More
Q4 2015

DVA Guru Trades in Q4 2015

Ray Dalio 31,945 sh (New)
Jim Simons 924,100 sh (+126.16%)
Mario Gabelli 39,963 sh (-4.31%)
Arnold Van Den Berg 268,133 sh (-6.22%)
» More
» Details

Insider Trades

Latest Guru Trades with DVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about DaVita HealthCare Partners Inc

Manning & Napier's Top 5 Stock Selections of Q1
Manning & Napier is an investment company that uses both macro and bottom-up approaches to select stocks. It had $47.8 billion in assets under management as of Dec. 31, 2014. Read more...
Texas Investor Arnold Van Den Berg Purchases 5 Stocks in Q1
Arnold Van Den Berg (Trades, Portfolio), the Austin-based founder of Century Management, invests in quality companies with growth prospects and strong reward-to-risk potential, among other characteristics in its analysis. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 28.16
DVA's P/E(ttm) is ranked lower than
56% of the 260 Companies
in the Global Medical Care industry.

( Industry Median: 25.40 vs. DVA: 28.16 )
Ranked among companies with meaningful P/E(ttm) only.
DVA' s P/E(ttm) Range Over the Past 10 Years
Min: 11.59  Med: 19.13 Max: 42.77
Current: 28.16
11.59
42.77
Forward P/E 15.46
DVA's Forward P/E is ranked higher than
58% of the 195 Companies
in the Global Medical Care industry.

( Industry Median: 16.00 vs. DVA: 15.46 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 28.16
DVA's PE(NRI) is ranked lower than
62% of the 197 Companies
in the Global Medical Care industry.

( Industry Median: 23.30 vs. DVA: 28.16 )
Ranked among companies with meaningful PE(NRI) only.
DVA' s PE(NRI) Range Over the Past 10 Years
Min: 11.63  Med: 19.44 Max: 42.69
Current: 28.16
11.63
42.69
P/B 2.66
DVA's P/B is ranked lower than
51% of the 307 Companies
in the Global Medical Care industry.

( Industry Median: 2.47 vs. DVA: 2.66 )
Ranked among companies with meaningful P/B only.
DVA' s P/B Range Over the Past 10 Years
Min: 2.37  Med: 3.32 Max: 7.46
Current: 2.66
2.37
7.46
P/S 1.01
DVA's P/S is ranked higher than
60% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 1.25 vs. DVA: 1.01 )
Ranked among companies with meaningful P/S only.
DVA' s P/S Range Over the Past 10 Years
Min: 0.77  Med: 1.20 Max: 2.33
Current: 1.01
0.77
2.33
PFCF 34.42
DVA's PFCF is ranked lower than
72% of the 199 Companies
in the Global Medical Care industry.

( Industry Median: 20.08 vs. DVA: 34.42 )
Ranked among companies with meaningful PFCF only.
DVA' s PFCF Range Over the Past 10 Years
Min: 7.52  Med: 16.92 Max: 42.59
Current: 34.42
7.52
42.59
POCF 12.81
DVA's POCF is ranked higher than
60% of the 271 Companies
in the Global Medical Care industry.

( Industry Median: 15.70 vs. DVA: 12.81 )
Ranked among companies with meaningful POCF only.
DVA' s POCF Range Over the Past 10 Years
Min: 5.19  Med: 9.66 Max: 17.92
Current: 12.81
5.19
17.92
EV-to-EBIT 14.96
DVA's EV-to-EBIT is ranked higher than
64% of the 286 Companies
in the Global Medical Care industry.

( Industry Median: 17.96 vs. DVA: 14.96 )
Ranked among companies with meaningful EV-to-EBIT only.
DVA' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.5  Med: 12.40 Max: 21.6
Current: 14.96
8.5
21.6
EV-to-EBITDA 10.26
DVA's EV-to-EBITDA is ranked higher than
67% of the 300 Companies
in the Global Medical Care industry.

( Industry Median: 13.84 vs. DVA: 10.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
DVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.8  Med: 9.70 Max: 17.2
Current: 10.26
6.8
17.2
PEG 1.89
DVA's PEG is ranked higher than
61% of the 76 Companies
in the Global Medical Care industry.

( Industry Median: 2.76 vs. DVA: 1.89 )
Ranked among companies with meaningful PEG only.
DVA' s PEG Range Over the Past 10 Years
Min: 0.41  Med: 1.31 Max: 2.94
Current: 1.89
0.41
2.94
Shiller P/E 26.66
DVA's Shiller P/E is ranked higher than
56% of the 68 Companies
in the Global Medical Care industry.

( Industry Median: 29.50 vs. DVA: 26.66 )
Ranked among companies with meaningful Shiller P/E only.
DVA' s Shiller P/E Range Over the Past 10 Years
Min: 19.53  Med: 30.44 Max: 70.02
Current: 26.66
19.53
70.02
Current Ratio 1.97
DVA's Current Ratio is ranked higher than
74% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 1.33 vs. DVA: 1.97 )
Ranked among companies with meaningful Current Ratio only.
DVA' s Current Ratio Range Over the Past 10 Years
Min: 0.39  Med: 1.89 Max: 5.97
Current: 1.97
0.39
5.97
Quick Ratio 1.89
DVA's Quick Ratio is ranked higher than
76% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 1.22 vs. DVA: 1.89 )
Ranked among companies with meaningful Quick Ratio only.
DVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.37  Med: 1.81 Max: 5.97
Current: 1.89
0.37
5.97
Days Inventory 5.50
DVA's Days Inventory is ranked higher than
82% of the 158 Companies
in the Global Medical Care industry.

( Industry Median: 16.82 vs. DVA: 5.50 )
Ranked among companies with meaningful Days Inventory only.
DVA' s Days Inventory Range Over the Past 10 Years
Min: 3.72  Med: 6.32 Max: 9.05
Current: 5.5
3.72
9.05
Days Sales Outstanding 45.70
DVA's Days Sales Outstanding is ranked higher than
51% of the 188 Companies
in the Global Medical Care industry.

( Industry Median: 46.01 vs. DVA: 45.70 )
Ranked among companies with meaningful Days Sales Outstanding only.
DVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.53  Med: 64.57 Max: 104.76
Current: 45.7
43.53
104.76
Days Payable 18.41
DVA's Days Payable is ranked lower than
77% of the 146 Companies
in the Global Medical Care industry.

( Industry Median: 42.47 vs. DVA: 18.41 )
Ranked among companies with meaningful Days Payable only.
DVA' s Days Payable Range Over the Past 10 Years
Min: 14.92  Med: 22.87 Max: 38.03
Current: 18.41
14.92
38.03

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.88
DVA's Price/Projected FCF is ranked higher than
78% of the 164 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. DVA: 0.88 )
Ranked among companies with meaningful Price/Projected FCF only.
DVA' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.83  Med: 1.17 Max: 6.25
Current: 0.88
0.83
6.25
Price/DCF (Earnings Based) 1.59
DVA's Price/DCF (Earnings Based) is ranked lower than
55% of the 47 Companies
in the Global Medical Care industry.

( Industry Median: 1.52 vs. DVA: 1.59 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.83
DVA's Price/Median PS Value is ranked higher than
69% of the 285 Companies
in the Global Medical Care industry.

( Industry Median: 1.01 vs. DVA: 0.83 )
Ranked among companies with meaningful Price/Median PS Value only.
DVA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.15  Med: 1.03 Max: 4.97
Current: 0.83
0.15
4.97
Price/Peter Lynch Fair Value 2.11
DVA's Price/Peter Lynch Fair Value is ranked higher than
56% of the 81 Companies
in the Global Medical Care industry.

( Industry Median: 2.18 vs. DVA: 2.11 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
DVA' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.39  Med: 1.09 Max: 8.16
Current: 2.11
0.39
8.16
Earnings Yield (Greenblatt) (%) 6.70
DVA's Earnings Yield (Greenblatt) (%) is ranked higher than
66% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 4.40 vs. DVA: 6.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DVA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.6  Med: 8.10 Max: 11.8
Current: 6.7
4.6
11.8
Forward Rate of Return (Yacktman) (%) 19.22
DVA's Forward Rate of Return (Yacktman) (%) is ranked higher than
74% of the 101 Companies
in the Global Medical Care industry.

( Industry Median: 10.86 vs. DVA: 19.22 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
DVA' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 12.5  Med: 21.20 Max: 51.1
Current: 19.22
12.5
51.1

More Statistics

Revenue(Mil) $13576
EPS $ 2.22
Beta0.69
Short Percentage of Float2.02%
52-Week Range $61.75 - 85.17
Shares Outstanding(Mil)211.00

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 13,614 14,678
EPS($) 3.76 4.00 4.12
EPS without NRI($) 3.76 4.00 4.12

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, FMS, FSNUY, BDUUF, SKHCY » details
Traded in other countries:TRL.Germany,
DaVita HealthCare Partners Inc was incorporated as a Delaware corporation in 1994. It is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease, or ESRD. The Company also provides administrative and management support services to a medical services joint venture in which the Company owns a 50% interests. As of December 31, 2014, it provided dialysis and administrative services in the U.S. through a network of 2,179 outpatient dialysis centers in 46 states and the District of Columbia, serving a total of approximately 173,000 patients. It also provides acute inpatient dialysis services in approximately 1,000 hospitals and related laboratory services throughout the United States. The United States dialysis and related lab services business. Home-based dialysis services consist of providing equipment and supplies, training, patient monitoring, on-call support services and follow-up assistance to patients who prefer and are able to receive either peritoneal dialysis or hemodialysis treatments in their homes. It provides hospital inpatient hemodialysis services are required for patients with acute kidney failure resulting from trauma, patients in early stages of ESRD and ESRD patients who require hospitalization for other reasons. It owns two separately incorporated, licensed, clinical laboratories, both located in Florida, specializing in ESRD patient testing. These specialized laboratories provide routine laboratory tests covered by the Medicare composite payment rate for dialysis and other physician-prescribed laboratory tests for ESRD patients. The Company's laboratories provide these tests predominantly for its own ESRD patients throughout the United States. It currently operates or provides management and administrative services to 29 outpatient dialysis centers, in which it either owns a non-controlling interest, or is wholly-owned by third parties, under management and administrative services agreements. It continues to face increased competition in the dialysis industry from large and medium-sized providers which compete directly with it for acquisition targets as well as for individual patients.
» More Articles for DVA

Headlines

Articles On GuruFocus.com
Alan Fournier Makes Modest Reductions in Middleby and Priceline Jan 12 2016 
Allergan Among Health Care Holdings in Alan Fournier's Portfolio Dec 15 2015 
Starting With GAAP Jun 11 2015 
Berkshire Hathaway: Business Value Exceeds Market Value May 26 2015 
Manning & Napier's Top 5 Stock Selections of Q1 Apr 21 2015 
A Further Peek Into Ted Weschler’s Thought Process Apr 21 2015 
Texas Investor Arnold Van Den Berg Purchases 5 Stocks in Q1 Apr 14 2015 
Andreas Halvorsen Keeps Buying DVA, HLT, ACT Apr 10 2015 
A Peek into Ted Weschler’s Thought Process Mar 20 2015 
Seven Subscribers Win Contest to Name Buffett's Stock Buys in Fourth Quarter Mar 08 2015 

More From Other Websites
[$$] U.S. Investigating DaVita HealthCare Unit Feb 11 2016
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita... Feb 11 2016
DaVita HealthCare Partners Inc Earnings Call scheduled for 5:00 pm ET today Feb 11 2016
DAVITA HEALTHCARE PARTNERS INC. Files SEC form 8-K, Other Events Feb 11 2016
DaVita HealthCare reports 4Q loss Feb 11 2016
DaVita HealthCare reports 4Q loss Feb 11 2016
4:08 pm DaVita beats by $0.15, reports revs in-line Feb 11 2016
DaVita HealthCare Partners Inc. 4th Quarter 2015 Results Feb 11 2016
Q4 2015 DaVita HealthCare Partners Inc Earnings Release - After Market Close Feb 11 2016
Can DaVita Healthcare (DVA) Q4 Earnings Pull a Surprise? Feb 09 2016
ABQ Health Partners parent firm launching into new kidney care space Feb 08 2016
DaVita HealthCare Partners Inc. Schedules 4th Quarter 2015 Investor Conference Call Feb 04 2016
Jim Rechtin Named President of HealthCare Partners' California Market Jan 21 2016
After-hours buzz: M, NFLX, UAL & more Jan 06 2016
DaVita (DVA) to Flourish on Inorganic Growth, High Debts a Drag Jan 05 2016
INVESTOR ALERT: Investigation of DaVita HealthCare Partners Inc. Announced by Law Offices of Howard... Jan 05 2016
Delivra Corp. Commences Trading on TSXV Jan 05 2016
IIROC Trading Resumption - DVA Jan 04 2016
IIROC Trading Resumption - DVA Jan 04 2016
Should You Follow Warren Buffett's Lead on DaVita? Dec 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK